Purefrex Cellfree Protein Synthesis Aims to Transform Biopharma RD

2026-10-25

GeneFrontier, a company under the Kaneka group, has developed PUREfrex®, a recombinant cell-free protein synthesis platform designed to address reproducibility and precision challenges in protein research and biopharmaceutical development. The system replaces conventional cell extracts with a defined mix of purified components, aiming to reduce background interference and improve control over protein expression. Its developer says the platform can support applications ranging from structural biology to drug discovery.

Core technology targets a defined synthesis environment

The PUREfrex system is based on the PURE framework developed at the University of Tokyo. It uses purified transcription and translation components, including ribosomes, amino acids, nucleotide triphosphates and tRNAs, combined in precise ratios to create a fully defined reaction system. According to the developer, this recombinant setup gives researchers greater control over synthesis and reduces nonspecific interference.

Unlike traditional lysate-based systems, which contain complex cellular components, the platform is intended to provide a low-background environment. That distinction is central to its use in experiments where reproducibility and precise protein expression are critical.

Performance profile

Performance indicator	PUREfrex characteristics
Contamination	RNase and beta-galactosidase levels controlled; endotoxin below 0.1 EU/µL
Synthesis yield	Up to about 600 µg/mL with PUREfrex® 2.0
System composition	Fully defined purified components; no active-cell background
Extended functions	Supports disulfide bond formation and chaperone-assisted folding

The platform’s performance profile reflects a broader effort in cell-free protein synthesis to move away from undefined cellular extracts and toward systems in which each reaction component can be controlled.

Iterations expand yield and scale options

PUREfrex was first introduced in 2011 and has since been updated. The PUREfrex® 2.0 version, released in 2015, increased yield by two- to tenfold and can synthesize model proteins at up to 600 µg/mL, according to the developer.

To accommodate different experimental scales, the company offers formats including a compact 100 µL PUREfrex® 2.0 mini starter kit. The range is designed to support the transition from small laboratory tests to high-throughput screening.

Applications span structural and synthetic biology

PUREfrex is positioned not only as a synthesis tool but also as a platform for structural biology, synthetic biology and biopharmaceutical discovery. Its flexibility allows researchers to add supplemental reagents for disulfide bond formation and chaperone-assisted folding, addressing folding challenges for difficult-to-express proteins.

Complex protein expression: Supplemental reagents support disulfide bond formation and chaperone-assisted folding for proteins that are difficult to express.
Special modifications and screening: The system supports incorporation of non-natural amino acids, small-molecule screening and ribosome display.
Membrane protein research: The platform is designed to provide a low-background environment for stable membrane protein expression.

The developer cites these applications as evidence that cell-free systems can serve as adaptable research tools beyond routine protein production.

Frequently Asked Questions

How does PUREfrex differ from conventional cell lysate systems?

Conventional systems use cell extracts with complex, undefined components, including endogenous nucleases and proteases. PUREfrex is a fully recombinant system built from purified components, which the developer says reduces background contamination, including RNase and endotoxin, and supports more reproducible protein synthesis.

Can the system support correct folding of complex proteins?

The platform supports supplemental reagents for disulfide bond formation and chaperone-assisted folding. According to the developer, this allows it to handle complex protein structures that can be difficult to express in standard cell-free systems.

What format is suggested for initial testing?

For researchers new to the system, the 100 µL PUREfrex® 2.0 mini starter kit is designed for small-scale experiments. It allows evaluation at lower cost before scaling to larger reaction volumes based on experimental needs.

Терапевтические экзосомы

Регенеративная эстетика

Экзосомы клинические

Экзосомальный бустер для кожи

раствор для заживления ран

Жидкость для личного ухода

косметика лица

Стволовые клетки

Иммунные клетки

Экзосомы, одобренные FDA